Apraclonidine Ophthalmic not checked

Alcon Research · FID 123472 · Apraclonidine 0.125% UDPF

FollowEvery change as it happens, and a Monday email
Stage
in the US
Next date
Phase 3 trial completes
Trials
2 active
2 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“Investigational ophthalmic solution applied topically to the eye in a unit dose preservative free formulation”In the company’s words, NCT07578363 on ClinicalTrials.gov
Tested for
Ocular Hyperemia (2 trials)
Main trialPhase 3
“The purpose of this study is to evaluate the efficacy and safety of an investigational ophthalmic solution in adults with ocular redness caused by minor eye irritations.”In the company’s words, NCT07578363 on ClinicalTrials.gov
Other names
FID 123472 · Apraclonidine 0.125% UDPF

Coming up2

Changes1

Last 90 days

Trials2

TrialPhaseCompletesWhat it tests
Phase 3Recruiting Nov 2026 An Investigation of FID 123472 Ophthalmic Solution to Vehicle for the Reduction of Ocular Redness in Adults
Phase 3Recruiting Feb 2027 Efficacy and Safety of FID 123472 Ophthalmic Solution for Ocular Redness in Adults
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow Apraclonidine Ophthalmic

Following is part of Solo: you see every change to Apraclonidine Ophthalmic the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in